Views and analysis

pharmaphorum editor in chief Jonah Comstock talks to Philip Gomez, CEO of Siga Technologies, about how his company’s

New countries stockpile antiviral TPOXX as monkeypox outbreak continues

https://pharmaphorum.com/r-d/new-countries-stockpile-antiviral-tpoxx-as-monkeypox-outbreak-continues/

Sales and Marketing/ Views & Analysis/ Views and analysis

Spotlight on Women in Science: Giulia Guerrini

Eloise McLennan giulia guerrini, Life Sciences, Medino, STEM, women in science 0 Comment

Around the world, women are making important contributions to life sciences. In this series, we chart the career

Spotlight on Women in Science: Giulia Guerrini

https://pharmaphorum.com/sales-marketing/spotlight-on-women-in-science-giulia-guerrini/

Market Access/ Views & Analysis/ Views and analysis

US frets over pharma supply chain security

Ben Hargreaves biologics, China, fda, pharma, US 0 Comment

The pandemic highlighted how fragile the global manufacturing network is, as supply of certain products was limited and

US frets over pharma supply chain security

https://pharmaphorum.com/market-access-2/us-frets-over-pharma-supply-chain-security/

Market Access/ Views & Analysis/ Views and analysis

IP is no barrier to COVID vaccine access, says industry

Amanda Barrell ABPI, COVID-19, IP frameworks 0 Comment

While proponents argue waiving IP on COVID-19 vaccines would better enable low- and middle-income countries to inoculate their

IP is no barrier to COVID vaccine access, says industry

https://pharmaphorum.com/market-access-2/ip-is-no-barrier-to-covid-vaccine-access-says-industry/

Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

Evaluate’s Orphan Drug Report shows rapid acceleration in the space

Jessica Hagen Andreas Hadjivasiliou, Evaluate, Orphan Drug Report, orphan drugs, Paul Verdin 0 Comment

Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the

Evaluate’s Orphan Drug Report shows rapid acceleration in the space

https://pharmaphorum.com/market-access-2/evaluates-orphan-drug-report-2022/

Market Access/ Views & Analysis/ Views and analysis

Six months after authorization, what do we know about Paxlovid?

mike.hammerton@pharmaphorum.com COVID-19, fda, Paxlovid, Pfizer 0 Comment

It has now been over six months since the FDA authorized Paxlovid in December 2021 “for the treatment

Six months after authorization, what do we know about Paxlovid?

https://pharmaphorum.com/market-access-2/six-months-after-authorization-what-do-we-know-about-paxlovid/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Time is motor neurons – the importance of newborn screening in SMA

mike.hammerton@pharmaphorum.com Deep Dive, Deep Dive: Market Access, market access, Mike Fraser, Novartis Gene Therapies, spinal muscular atrophy 0 Comment

Spinal muscular atrophy (SMA) is a devastating, genetic neuromuscular disease caused by a lack of a functional SMN1

Time is motor neurons – the importance of newborn screening in SMA

https://pharmaphorum.com/market-access-2/time-is-motor-neurons-the-importance-of-newborn-screening-in-sma/

Podcast/ Slider in video/ Video/ Views and analysis

Why diverse clinical trials matter: the pharmaphorum podcast

Jonah Comstock Abbot, clinical trials, Dr. Jennifer Jones-McMeans 0 Comment

In this episode of the pharmaphorum podcast, editor in chief Jonah Comstock welcomes Dr. Jennifer Jones-McMeans, divisional vice

Why diverse clinical trials matter: the pharmaphorum podcast

https://pharmaphorum.com/podcast/why-diverse-clinical-trials-matter/

Market Access/ Patients/ Views & Analysis/ Views & Analysis/ Views and analysis

Questions linger as England’s Innovative Medicines Fund kicks off

Leela Barham Innovative Medicines Fund, market access, NHS, NICE 0 Comment

In part one of this two-article series on the latest on England’s Innovative Medicines Fund (IMF), Leela Barham

Questions linger as England’s Innovative Medicines Fund kicks off

https://pharmaphorum.com/market-access-2/questions-linger-as-englands-innovative-medicines-fund-kicks-off/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

Views and analysis

Login